Barclays PLC Grows Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Barclays PLC raised its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 79.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 106,174 shares of the company’s stock after acquiring an additional 47,059 shares during the period. Barclays PLC’s holdings in Nautilus Biotechnology were worth $303,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of NAUT. SG Americas Securities LLC bought a new position in Nautilus Biotechnology in the 3rd quarter worth about $50,000. The Manufacturers Life Insurance Company bought a new position in shares of Nautilus Biotechnology in the third quarter valued at approximately $67,000. China Universal Asset Management Co. Ltd. grew its stake in Nautilus Biotechnology by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after acquiring an additional 9,404 shares in the last quarter. MetLife Investment Management LLC bought a new stake in Nautilus Biotechnology during the 3rd quarter worth approximately $87,000. Finally, Renaissance Technologies LLC increased its holdings in Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after acquiring an additional 14,100 shares during the period. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Up 1.6 %

NASDAQ:NAUT opened at $1.93 on Tuesday. The stock has a market cap of $242.33 million, a P/E ratio of -3.45 and a beta of 1.20. The business’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.42. Nautilus Biotechnology, Inc. has a twelve month low of $1.61 and a twelve month high of $3.12.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. During the same quarter in the previous year, the company earned ($0.13) earnings per share. On average, equities research analysts expect that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and cut their price target for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.